BioCorRx (OTC:BICX) said today that it inked a confidentiality agreement with the National Institute on Drug Abuse, which will allow the group to share information and potentially work together on R&D and commercialization of BioCorRx’s therapies for opioid use disorder.
The National Institutes of Health division has also agreed to participate as an observer at the FDA’s pre-IND meeting for BioCorRx’s naltrexone implant slated to take place on Jan. 24.
The company’s CEO, Brady Granier, plans to meet with NIDA next week to seek technical advice on the implant, BICX102, the company reported.
“We are honored that NIDA has agreed to engage with us through this process. Our desire is to get this valuable treatment option to market as quickly as possible so that we can help those suffering from opioid use disorder, as well as those suffering from alcohol use disorder,” Granier said in prepared remarks.
“The medical community and government entities have shown strong interest in our products and we have seen a high demand for an antagonist therapy that can last several months. We look forward to the next meeting with NIDA and for their attendance at our upcoming FDA meeting. We believe this naltrexone product can save many more lives if approved and becomes more widely accepted by payers.”
